TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02054143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
Study: NCT04719676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core strength training using unstable surface
Description: Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on unstable surface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The stable surface would be gym floor.
Description: Training would include big 3 exercises as described by McGill. These include the curl-up, side bridge, and quadruped position on stable gym Floor
Study: NCT05439460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: 5 subjects will get Phenylephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Description: 5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arginine Vasopressin
Description: 5 subjects will get Arginine Vasopressin during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
Study: NCT00707655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Eight weekly infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: Eight weekly infusions
Study: NCT02683694

Intervention type: DEVICE
Group type: OTHER
Intervention: iOCT
Description: the number of subjects that can be peeled without dye are assessed
Study: NCT02854904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine intervention
Description: Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled
Study: NCT01819311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Task
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
Study: NCT02343276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline solution 10 ml) in radial artery after sheath insertion
Study: NCT04234776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: (0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: (0,75 mg/kg) saline solution (15 mg) Escitalopram (5 mg) Aripiprazole

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cognition
Description: Composite tools
Study: NCT03142035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest 2 MG
Description: Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gonapeptyl
Description: gonadotropic releasing hormone agonist

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IVF/IVF+ART
Description: In-vitro fertilization +/- assisted reproductive technology

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVF/IVF+ART
Description: In-vitro fertilization +/- assisted reproductive technology

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/IVF+ART
Description: In-vitro fertilization +/- assisted reproductive technology
Study: NCT02668822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)
Description: Medicated vaginal ring

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal ring
Description: Placebo vaginal ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
Study: NCT00594620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flav-ein capsules
Description: Soy/isoflavone supplementation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02418117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stereolitographic template
Description: Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
Study: NCT06231459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 140 mg was administered intramuscularly every two weeks at the discretion of their physiciansm according to LDLc response. Clinical-demographic and anthropometry data were collected during a direct interview. Blood sample was processed to obtain glycated hemoglobin complete blood count and serum lipids. Likewise, flow cytometry was used to characterize baseline circulating M1-, M2-macrophages and monocytes. Multiplexing of plasma samples was used to compare plasma fraktaline, IL-1, IL-4, IL-6, IL-8, IL-10, MCP-1 and TNF-alpha. Endpoints consisted of: 1) lower serum lipids; 2) modification of pro-inflammatory mediators (neutrophils, lymphocytes, NtLR, soluble pro-inflammatory cytokines).
Study: NCT00903747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: 2-10 mg prucalopride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: moxifloxacin
Description: 400 mg moxifloxacin (Group 2a)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (Group 2b)
Study: NCT03252314

Intervention type: DEVICE
Intervention: Second-generation hydrogel coils
Description: Hydrogel coils 90% by length
Study: NCT04195659

Intervention type: PROCEDURE
Intervention: Mastectomy and chest masculinization
Description: A surgical procedure in which the breasts are removed and the chest is given a masculine contour.
Study: NCT03524105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program for Parents (Parenting Program)
Description: Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of \~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thrive Professional Learning
Description: Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
Study: NCT02311309

Intervention type: OTHER
Intervention: Control
Description: Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration \>8 g/dL.

Intervention type: OTHER
Intervention: Unanticipated bleeding
Description: Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration \< 8 g/dL.
Study: NCT02357641

Intervention type: OTHER
Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome
Description: retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
Study: NCT02152592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCM/Oxy1
Description: Controlled Release oxycodone 10 mg orally twice a day for 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCM/Oxy2
Description: CR oxycodone 10 mg orally twice a day for 48 hours
Study: NCT01523314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone - Cyclodextrin eye drops
Description: The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravitreal Avastin injection +/- macular laser
Description: The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
Study: NCT03145194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 2 x 90mg Ticagrelor tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x matching placebo tablets
Study: NCT03263936

Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5

Intervention type: DRUG
Group type: OTHER
Intervention: Vorinostat
Description: Age \<18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.

Intervention type: DRUG
Group type: OTHER
Intervention: Filgrastim (G-CSF)
Description: Given on days 5 until evidence of ANC recovery (\>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: 2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
Study: NCT05597059

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Prediction
Description: Machine Learning Prediction

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Prediction
Description: Machine Learning Prediction

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Prediction
Description: Machine Learning Prediction

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Prediction
Description: Machine Learning Prediction

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Prediction
Description: Machine Learning Prediction

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Prediction
Description: Machine Learning Prediction
Study: NCT01030458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine 5/10 mg per day plus valsartan 160 mg/day
Description: Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day
Description: hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
Study: NCT04234776

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognition
Description: Composite tools
Study: NCT05641038

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peloid treatment
Description: The patients in the first group; Peloid was applied to both feet at 42 °C for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. Peloid was applied in a layer of approximately 1.5-2 cm thick, then the foot was wrapped in a nylon bag and covered with a towel. After 20 minutes of application, the peloid layer was removed and disposed of in medical waste. The treatment area was cleaned with soft cloths moistened with hot water and the session was ended. In addition to peloid therapy, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for the patients to do simultaneously.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paraffin treatment
Description: The patients in the second group were given paraffin treatment on both feet by dipping method, for 2 weeks, 5 days a week, 10 sessions in total, 20 minutes each session. After the foot was dipped and removed 10 times, it was wrapped in a nylon bag and left for 20 minutes. Then the paraffin was peeled off the feet and disposed of in medical waste. Likewise, a home exercise program including joint range of motion, stretching and strengthening exercises for the 1st MTF with 3 sets of 10 repetitions was described for them to do simultaneously.
Study: NCT03179280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
Study: NCT03248245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LOG-model
Description: Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Ordinary practices related to interprofessional team collaboration
Study: NCT04246580

Intervention type: PROCEDURE
Intervention: Indocyanine green-guided systematic pelvic lymphadenectomy
Description: Injection of Indocyanine green within the uterine cervix before to perform laparoscopic/robotic systematic pelvic lymphadenectomy
Study: NCT02981277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transcricoid injection
Description: Lignocaine delivery using Transcricoid Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spray as you go
Description: Lignocaine delivery using Spray as you go method
Study: NCT01672606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Partial neuromuscular blockade with rocuronium with a TOF 0.70
Study: NCT00623467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
Study: NCT04131517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Study Medication: Padsevonil Dosage formulation: Oral tablets; 400 mg BID (Part 1) and 200 mg BID (Part 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon 30®
Description: Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon 30®
Description: Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
Study: NCT00347763

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10% permethrin in water applied as low volume spray
Study: NCT03550131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Innovations in Dementia Empowerment and Action (IDEA)
Description: The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reducing Disabilities in Alzheimer's Disease (RDAD)
Description: The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
Study: NCT04395352

Intervention type: DEVICE
Intervention: Endocuff Vision (ECV)
Description: Detachable disposable (single-use) device that fits over the distal colonoscope end.
Study: NCT03664284

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous disinfection
Description: The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
Study: NCT00624728

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F Fluorothymidine PET CT
Description: 18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (\>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (\> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction.
Study: NCT01864798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Study: NCT04966195

Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body raiotherapy
Description: stereotactic body radiotherapy of hepatocellular carcinoma patients with portal vein tumor thrombosis
Study: NCT03487640

Intervention type: PROCEDURE
Intervention: TARMR
Description: Transanal resection of rectal mucosa for at least 5cm in length.

Intervention type: PROCEDURE
Intervention: LARSC
Description: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
Study: NCT02104804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg
Description: Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Saxagliptin
Description: Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
Study: NCT01432197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADL intervention
Description: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
Study: NCT05272527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition to Motherhood Program
Description: Transition to Motherhood program includes 5 sessions. The first session covers the pregnancy process, the second session deals with the birth process, the third session deals with the postpartum period, the fourth session deals with infant care, and the fifth session deals with breast milk and breastfeeding and immunity. Trainings are online. In addition to the lecture technique, the training includes auxiliary techniques such as models, videos, case studies, training cards, and applied demonstrations. The program was completed by telephone follow-up in the first and fourth weeks postpartum.
Study: NCT00717366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: Will be administered IV, every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-Epoetin Beta
Description: Will be administered IV, every 4 weeks.
Study: NCT02695706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laboratoires Mercurochrome Reparador
Description: Developed for the treatment of damaged or fragile skin.